Weekly Digests



Working 9 to 5: circadian rhythm in immune cells affects immunotherapy

December 21, 2022

While it is known that both the innate and adaptive arms of the immune system follow circadian rhythms, the mechanisms behind these rhythms and their effects on vaccination treatment efficacy, particularly in the cancer setting, remain largely unknown. Two recent papers by Wang et al. in Nature and Cervantes-Silva and Carroll et al...

MEK inhibition increases TAAs and targetable pMHCs

December 14, 2022

In NRAS/BRAF-mutant melanoma, MEK and BRAF inhibitors (MEKi/BRAFi) are known to increase expression of tumor antigens and upregulate pMHCs, leading to increased antitumor immune responses. However, MEK/BRAF inhibitors alone are not usually effective long-term, and when used in combination with immunotherapies, can cause high toxicity. To better understand the effects of MEKi/BRAFi and...

Bring in the B cells with an immunotoxin

December 7, 2022

The tumor-associated antigen mesothelin (MSLN) is expressed by mesothelioma and other types of cancer. LMB-100 is an immunotoxin consisting of a Fab recognizing human MSLN that is linked to a toxin (Pseudomonas exotoxin A), which induces direct tumor cell killing by arresting protein synthesis. Liu et al. investigated in a mesothelioma mouse model...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.